Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Approaches in anticoagulation: rationales for target positioning.

Heike A Wieland1, Volker Laux, Detlef Kozian

  • 1Aventis Pharma Deutschland GmbH, Disease Group of Thrombotic and Degenerative Joint Diseases, Industriepark Höchst, 65926 Frankfurt, Germany. heike.wieland@aventis.com

Current Opinion in Investigational Drugs (London, England : 2000)
|May 9, 2003
PubMed
Summary

New small-molecule anticoagulants aim to overcome limitations of current therapies like heparin and warfarin. This review explores promising drug targets for faster-acting, safer antithrombotic treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantification of vehicular <i>versus</i> uncorrelated Li<sup>+</sup>-solvent transport in highly concentrated electrolytes <i>via</i> solvent-related Onsager coefficients.

Physical chemistry chemical physics : PCCP·2024
Same author

Identification of CRTH2 as a New PPARγ-Target Gene in T Cells Suggested CRTH2 Dependent Conversion of T<sub>h</sub>2 Cells as Therapeutic Concept in COVID-19 Infection.

ImmunoTargets and therapy·2024
Same author

Novel and Proven Models of Public, Private, and Public-Private Partnerships in Healthcare: An Update.

Handbook of experimental pharmacology·2024
Same author

Pr<sup>3+</sup>-doped YPO<sub>4</sub> nanocrystal embedded into an optical fiber.

Scientific reports·2024
Same author

Evaluating Strategies to Enhance Li Transference in Salt-in-Ionic Liquid Electrolytes: Mixed Anions, Coordinating Cations, and High Salt Concentration.

The journal of physical chemistry. B·2024
Same author

Short-term predictor for COVID-19 severity from a longitudinal multi-omics study for practical application in intensive care units.

Talanta·2023

Area of Science:

  • Pharmacology and Toxicology
  • Hematology
  • Drug Discovery

Background:

  • Heparin and warfarin are standard anticoagulants but have limitations including slow onset and narrow therapeutic windows.
  • Existing treatments pose challenges for prophylaxis and treatment of thrombus-based diseases.
  • There is a need for anticoagulants with immediate onset, oral bioavailability, and improved safety profiles.

Purpose of the Study:

  • To review current concepts and hypotheses in anticoagulant approaches.
  • To evaluate various antithrombotic strategies, including animal models, genetic disorders, and compound profiling.
  • To identify promising drug targets in antithrombotic therapy by examining coagulation cascade factors and fibrinolysis modulators.

Main Methods:

  • Literature review of current anticoagulant research.

Related Experiment Videos

  • Analysis of animal models and genetic disorders relevant to thrombosis.
  • Evaluation of compound profiling for novel anticoagulant agents.
  • Examination of coagulation cascade and fibrinolysis pathways for potential drug targets.

    • Main Results:

    • Current anticoagulants (heparin, warfarin) have significant clinical limitations.
    • Ideal anticoagulants require rapid action, oral bioavailability, and enhanced safety.
    • Several factors in the coagulation cascade and fibrinolysis represent potential therapeutic targets.

    Conclusions:

    • Novel small-molecule non-peptide inhibitors offer potential for improved antithrombotic therapy.
    • Targeting specific factors in coagulation and fibrinolysis may lead to safer and more effective anticoagulants.
    • Further research into these targets is warranted to develop next-generation antithrombotic drugs.